Sanofi to acquire Qunol

Published On 2023-07-28 08:00 GMT   |   Update On 2023-07-28 08:01 GMT
Advertisement

Paris: Sanofi has announced it has entered into a definitive agreement to acquire ownership of Qunol, a U.S.-based brand in health & wellness. This transaction will strengthen Sanofi’s Consumer Healthcare’s (CHC) Vitamin, Mineral and Supplements (VMS) category.

"With Qunol’s CoQ10 in heart health and Turmeric in joint health, CHC at Sanofi adds a trusted, profitable double-digit growth brand to its U.S. portfolio, focused on chronic conditions with growing consumer demand," the release stated. With this acquisition, Sanofi continues to pursue growth opportunities and value creation for its consumer healthcare business.

Advertisement

Julie Van Ongevalle, Executive Vice President, Consumer Healthcare, Sanofi said, “The acquisition of Qunol further strengthens our portfolio in the wellness category. It taps into the growing ‘healthy aging’ segment and fills one of our white spaces in the US, unlocking an opportunity for us to build on our U.S. presence and accelerate our growth. VMS now functions as long-term support for overall health and wellness where proactive preventive health has become the new norm post-pandemic. We are excited to welcome Qunol and, with this addition to our consumer healthcare portfolio, reinforce our commitment to bring more health into the hands of people.”

Qunol CoQ10 and Turmeric products are both backed by science literature and strong market positioning in their segments. The Qunol brand will benefit from Sanofi’s CHC resources to expand into other chronic conditions and develop its footprint outside the U.S.

Peter Boutros, CEO, Quten Research Institute, LLC said, “Qunol is looking forward to joining Sanofi’s consumer healthcare team and developing synergies that will further drive brand awareness for our products with our consumers and customers. With Sanofi, we have the opportunity to further grow in the U.S. and beyond, tapping into Sanofi Consumer Healthcare’s commercial breadth and strength.”

Sanofi entered into a definitive agreement to acquire ownership of Qunol, subject to customary closing conditions, including applicable regulatory approvals. The acquisition is expected to close Q3 2023.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News